Advanced

High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer

Hjelm, Barbara; Brennan, Donal J.; Zendehrokh, Nooreldin LU ; Eberhard, Jakob LU ; Nodin, Björn LU ; Gaber, Alexander LU ; Ponten, Fredrik; Johannesson, Henrik; Smaragdi, Kristina and Frantz, Christian, et al. (2011) In Proteomics Clinical Applications 5(11-12). p.624-635
Abstract
Purpose: In this study, we investigated the prognostic impact of human RBM3 expression in colorectal cancer using tissue microarray-based immunohistochemical analysis. Experimental design: One polyclonal antibody and four monoclonal anti-RBM3 antibodies were generated and epitope mapped using two different methods. Bacterial display revealed five distinct epitopes for the polydonal antibody, while the four mouse monoclonal antibodies were found to bind to three of the five epitopes. A peptide suspension bead array assay confirmed the five epitopes of the polydonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. Antibody specificity was confirmed by Western blotting and immunohistochemistry,... (More)
Purpose: In this study, we investigated the prognostic impact of human RBM3 expression in colorectal cancer using tissue microarray-based immunohistochemical analysis. Experimental design: One polyclonal antibody and four monoclonal anti-RBM3 antibodies were generated and epitope mapped using two different methods. Bacterial display revealed five distinct epitopes for the polydonal antibody, while the four mouse monoclonal antibodies were found to bind to three of the five epitopes. A peptide suspension bead array assay confirmed the five epitopes of the polydonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. Antibody specificity was confirmed by Western blotting and immunohistochemistry, including siRNA-mediated knock-down. Two of the antibodies (polydonal and monoclonal) were subsequently used to analyze RBM3 expression in tumor samples from two independent colorectal cancer cohorts, one consecutive cohort (n = 270) and one prospectively collected cohort of patients with cancer of the sigmoid colon (n = 305). RBM3-expression was detected, with high correlation between both antibodies (R = 0.81, p < 0.001). Results: In both cohorts, tumors with high nuclear RBM3 staining had significantly prolonged the overall survival. This was also confirmed in multivariate analysis, adjusted for established prognostic factors. Conclusion and clinical relevance: These data demonstrate that high tumor-specific nuclear expression of RBM3 is an independent predictor of good prognosis in colorectal cancer. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Antibodies, Colorectal cancer, Epitope mapping, Prognosis, RNA-binding, protein
in
Proteomics Clinical Applications
volume
5
issue
11-12
pages
624 - 635
publisher
John Wiley & Sons
external identifiers
  • wos:000298334000006
  • scopus:84855183064
ISSN
1862-8354
DOI
10.1002/prca.201100020
language
English
LU publication?
yes
id
f6536c61-e44f-43da-b020-1c6fe68fa647 (old id 2333085)
date added to LUP
2012-02-01 07:36:08
date last changed
2017-09-10 03:27:14
@article{f6536c61-e44f-43da-b020-1c6fe68fa647,
  abstract     = {Purpose: In this study, we investigated the prognostic impact of human RBM3 expression in colorectal cancer using tissue microarray-based immunohistochemical analysis. Experimental design: One polyclonal antibody and four monoclonal anti-RBM3 antibodies were generated and epitope mapped using two different methods. Bacterial display revealed five distinct epitopes for the polydonal antibody, while the four mouse monoclonal antibodies were found to bind to three of the five epitopes. A peptide suspension bead array assay confirmed the five epitopes of the polydonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. Antibody specificity was confirmed by Western blotting and immunohistochemistry, including siRNA-mediated knock-down. Two of the antibodies (polydonal and monoclonal) were subsequently used to analyze RBM3 expression in tumor samples from two independent colorectal cancer cohorts, one consecutive cohort (n = 270) and one prospectively collected cohort of patients with cancer of the sigmoid colon (n = 305). RBM3-expression was detected, with high correlation between both antibodies (R = 0.81, p &lt; 0.001). Results: In both cohorts, tumors with high nuclear RBM3 staining had significantly prolonged the overall survival. This was also confirmed in multivariate analysis, adjusted for established prognostic factors. Conclusion and clinical relevance: These data demonstrate that high tumor-specific nuclear expression of RBM3 is an independent predictor of good prognosis in colorectal cancer.},
  author       = {Hjelm, Barbara and Brennan, Donal J. and Zendehrokh, Nooreldin and Eberhard, Jakob and Nodin, Björn and Gaber, Alexander and Ponten, Fredrik and Johannesson, Henrik and Smaragdi, Kristina and Frantz, Christian and Hober, Sophia and Johnson, Louis Banka and Påhlman, Sven and Jirström, Karin and Uhlen, Mathias},
  issn         = {1862-8354},
  keyword      = {Antibodies,Colorectal cancer,Epitope mapping,Prognosis,RNA-binding,protein},
  language     = {eng},
  number       = {11-12},
  pages        = {624--635},
  publisher    = {John Wiley & Sons},
  series       = {Proteomics Clinical Applications},
  title        = {High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer},
  url          = {http://dx.doi.org/10.1002/prca.201100020},
  volume       = {5},
  year         = {2011},
}